These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14734477)

  • 41. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
    Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
    Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An M2 Rather than a T
    Lee DH; Ghiasi H
    J Virol; 2018 May; 92(10):. PubMed ID: 29491152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.
    Wong RJ; Kim SH; Joe JK; Shah JP; Johnson PA; Fong Y
    J Am Coll Surg; 2001 Jul; 193(1):12-21. PubMed ID: 11442249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
    Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.
    Liu RB; Rabkin SD
    Chin Med J (Engl); 2005 Feb; 118(4):307-12. PubMed ID: 15740669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
    Kimata H; Takakuwa H; Goshima F; Teshigahara O; Nakao A; Kurata T; Sata T; Nishiyama Y
    Hepatogastroenterology; 2003; 50(52):961-6. PubMed ID: 12845959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
    Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL
    Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.
    Broberg EK; Peltoniemi J; Nygårdas M; Vahlberg T; Röyttä M; Hukkanen V
    J Virol; 2004 Dec; 78(23):13139-52. PubMed ID: 15542666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
    Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
    PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
    Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
    Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
    Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
    Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.
    Kramer MG; Masner M; Casales E; Moreno M; Smerdou C; Chabalgoity JA
    BMC Cancer; 2015 Sep; 15():620. PubMed ID: 26347489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.
    Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D
    Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.